Correlation Between Milestone Pharmaceuticals and Inozyme Pharma
Can any of the company-specific risk be diversified away by investing in both Milestone Pharmaceuticals and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Milestone Pharmaceuticals and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Milestone Pharmaceuticals and Inozyme Pharma, you can compare the effects of market volatilities on Milestone Pharmaceuticals and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Milestone Pharmaceuticals with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Milestone Pharmaceuticals and Inozyme Pharma.
Diversification Opportunities for Milestone Pharmaceuticals and Inozyme Pharma
-0.76 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Milestone and Inozyme is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Milestone Pharmaceuticals and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Milestone Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Milestone Pharmaceuticals are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Milestone Pharmaceuticals i.e., Milestone Pharmaceuticals and Inozyme Pharma go up and down completely randomly.
Pair Corralation between Milestone Pharmaceuticals and Inozyme Pharma
Given the investment horizon of 90 days Milestone Pharmaceuticals is expected to generate 1.17 times more return on investment than Inozyme Pharma. However, Milestone Pharmaceuticals is 1.17 times more volatile than Inozyme Pharma. It trades about 0.28 of its potential returns per unit of risk. Inozyme Pharma is currently generating about -0.67 per unit of risk. If you would invest 145.00 in Milestone Pharmaceuticals on August 29, 2024 and sell it today you would earn a total of 40.00 from holding Milestone Pharmaceuticals or generate 27.59% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Milestone Pharmaceuticals vs. Inozyme Pharma
Performance |
| Timeline |
| Milestone Pharmaceuticals |
| Inozyme Pharma |
Milestone Pharmaceuticals and Inozyme Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Milestone Pharmaceuticals and Inozyme Pharma
The main advantage of trading using opposite Milestone Pharmaceuticals and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Milestone Pharmaceuticals position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.The idea behind Milestone Pharmaceuticals and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |